November 29, 2023
As Japan’s drug pricing debate towards the FY2024 reform heads into the homestretch, discussions to review the cost-effectiveness assessment (CEA) scheme are also reaching their endgame. The pharmaceutical industry is now in a lobbying frenzy mode to push back a...read more